



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_209_26

You asked:

Question 1. How many patients were treated in the last 4 months (December to March 2026) by the dermatology department with each of the following products:

- **Abrocitinib**
- **Acitretin**
- **Alitretinoin**
- **Azathioprine**
- **Baricitinib**
- **Ciclosporin**
- **Dupilumab**
- **Lebrikizumab**
- **Methotrexate**
- **Mycophenolate mofetil**
- **Pimecrolimus**
- **Tacrolimus ointment**
- **Tralokinumab**
- **Upadacitinib**
- **Nemolizumab**

Please find below three tables populated with the information Medicines Management are able to provide at this current time. The Secondary Care data period relates to December 2025 to March 2026, and the Primary Care Data period relates to October 25 to January 2026 the latest data available.

Unfortunately, due to the way the data is recorded in our systems we are not able to provide all the data in the format of number of patients. However, where we are unable to provide number of patients we have provided number of issues or number of items.

Secondary Care

Medicines	Number of Patients
Abrocitinib	11
Baricitinib	5
Dupilumab	289
Lebrikizumab	19
Tralokinumab	6
Upadacitinib	140
Nemolizumab	24

Secondary Care

Medicine	Pack Size	Number of Issues
Acitretin	60 Capsule Pack	318
Alitretinoin	30 Capsule Pack	39
Azathioprine	56 Tablet Pack	4
Azathioprine	28 Tablet Pack	2
Azathioprine	200 mL Bottle	1
Ciclosporin	30 Capsule Pack	41
Methotrexate	1 Pre-Filled Pen Pack	1504
Methotrexate	1 Pre-Filled Syringe Pack	16
Methotrexate	24 Tablet Pack	5
Mycophenolate mofetil	50 Tablet Pack	303.52
Pimecrolimus	0	2
Tacrolimus ointment	30 g Pack	42

Primary Care

Medicine	Number of Items
Methotrexate	5118
Azathioprine	1094
Azathioprine 25mg Tablets	207
Azathioprine 50mg Tablets	865
Azathioprine 100mg Tablets	12
Mycophenolate	504
Ciclosporin (eye Anti Inflam)	7
Ciclosporin_Eye Oint 0.2%	2
Ciclosporin_Eye Dps 0.1% 0.3ml Ud	62
Pimecrolimus_Crm 1%	56
Tacrolimus_Oint 0.1%	231
Tacrolimus_Oint 0.03%	63
Acitretin	4
Acitretin 25mg Capsules	4
Azathioprine 75mg Tablets	3
Ciclosporin_Eye Oint 0.2% P/f	2

- **Phototherapy (UVB or PUVA) - for Atopic Dermatitis only – 7 Patients**

Question 2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

- **Abrocitinib**
- **Baricitinib**
- **Dupilumab**
- **Lebrikizumab**
- **Tralokinumab**
- **Upadacitinib**

- **Nemolizumab**

***Patients are considered 'new patients initiated' on a treatment if they have not been previously treated with any of the other named treatments above since 1st April 2025 prior to initiation.**

e.g. Patient initiated on Lebrikizumab in Dec 2025 - March 2026 (has not previously been treated with Abro, Bari, Dupi, Tralo, Upada, Nemo since March 2025)

We can confirm that the Health Board does not centrally record this information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act. Therefore, we are unable to provide.

Question 3. How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products:

- **Dupilumab**
- **Nemolizumab**

Please see response to Q2 – Section 12 applied.